SCHEMBL19253834

SCHEMBL19253834

O=c1[nH]c(NC(c2ccccc2)(c2ccccc2)c2ccccc2)nc2[nH]cc(CNCCCc3ccccc3)c12

nearest known ligand 0.39

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MPO P05164 2/20 0.39
SIGMAR1 Q99720 6/20 0.35
SLC6A4 P31645 1/20 0.34
SLC6A5 Q9Y345 1/20 0.33
TYMS P04818 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17652035 0.89 LMNA (0.35) TYMS
SCHEMBL17652081 0.87 LMNA (0.36)
SCHEMBL19275107 0.85 MPO (0.41) MPOSIGMAR1SLC6A4TYMS
SCHEMBL19253836 0.82 TYMS (0.34) TYMS
SCHEMBL17652074 0.81 TYMS (0.48) TYMS
SCHEMBL19270442 0.81 MPO (0.43) MPOSIGMAR1SLC6A4
Hydrochloric Acid SCHEMBL17652090 0.80 TYMS (0.48) TYMS
SCHEMBL17652032 0.77 TYMS (0.34) TYMS
SCHEMBL17652009 0.75 KMT2A (0.35) TYMS
SCHEMBL25387199 0.73 TAAR1 (0.36) TYMS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11518765-B2 Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases THE PROVOST, THE FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) 2022-12-06 US disclosed
US-11229652-B2 Treatments for autoimmune disease THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) 2022-01-25 US disclosed
US-20210024529-A1 SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE DISEASES THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) 2021-01-28 US disclosed
US-10793572-B2 Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases THE PROVOST FELLOWS FOUNDATION SCHOLARS AND THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH (IE) 2020-10-06 US disclosed
EP-3201198-B1 SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE DISEASES THE PROVOST FELLOWS FOUND SCHOLARS AND THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIV (IE) 2020-07-29 EP disclosed
EP-3200798-B1 TREATMENTS FOR AUTOIMMUNE DISEASE THE PROVOST FELLOWS FOUND SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIV T (IE) 2019-05-22 EP disclosed
US-20180256583-A1 TREATMENTS FOR AUTOIMMUNE DISEASE THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) 2018-09-13 US disclosed
US-20170258797-A1 TREATMENTS FOR AUTOIMMUNE DISEASE THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH (IE) 2017-09-14 US disclosed
US-20170240553-A1 SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE DISEASES THE PROVOST FELLOWS FOUNDATION SCHOLARS AND THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH (IE) 2017-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170240553-A1 SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE DISEASES TYMS, DPYD, C5 MPO 1456/4885SIGMAR1 3577/4885SLC6A4 4115/4885
US-11518765-B2 Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases TYMS, C5, HRH3 MPO 1966/4885SIGMAR1 3687/4885SLC6A4 4266/4885
US-20180256583-A1 TREATMENTS FOR AUTOIMMUNE DISEASE QTRT1, QTRT2, HPRT1 MPO 144/4885SIGMAR1 4483/4885SLC6A4 3152/4885
US-10793572-B2 Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases TYMS, DPYD, C5 MPO 1456/4885SIGMAR1 3577/4885SLC6A4 4115/4885
US-20210024529-A1 SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE DISEASES TYMS, C5, HRH3 MPO 1966/4885SIGMAR1 3687/4885SLC6A4 4266/4885
US-20170258797-A1 TREATMENTS FOR AUTOIMMUNE DISEASE QTRT1, QTRT2, HPRT1 MPO 144/4885SIGMAR1 4483/4885SLC6A4 3152/4885
US-11229652-B2 Treatments for autoimmune disease QARS1, QTRT1, QTRT2 MPO 199/4885SIGMAR1 4851/4885SLC6A4 3750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.